4-Methyl-6,7-dihydro-4<i>H</i>-triazolo[4,5-<i>c</i>]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical CandidateMichael A. Letavic, Anindya Bhattacharya, Pascal Bonaventure et al.|Journal of Medicinal Chemistry|2017Cited by 69
A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334Brian Lord, Anindya Bhattacharya, Michael K. Ameriks et al.|European Journal of Pharmacology|2015Cited by 57
Identification of (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptorDevin M. Swanson, Michael A. Letavic, Brad M. Savall et al.|Journal of Medicinal Chemistry|2016Cited by 37
Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonistsDale A. Rudolph, Michael A. Letavic, Jesús Alcázar et al.|Bioorganic & Medicinal Chemistry Letters|2015Cited by 33